Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients

NCT06908772 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

390

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression

Interventions

DRUG: Glumetinib Tablets
DRUG: Osimertinib Mesylate Tablets
DRUG: Glumetinib Tablets Placebo

Sponsor

Shanghai JMT-Bio Inc.